Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE) on September 8, 2023. Pursuant to the Transaction, Biocure Technology Inc. will issue common shares in its capital to the shareholders in the capital of Atriva on the basis of a proposed exchange ratio such that, following the closing of the Transaction, on a fully diluted basis, approximately 75% of the securities of the Resulting Issuer will be held by current Atriva securityholders, together with subscribers in a concurrent financing, and approximately 25% of the securities of the Resulting Issuer will be held by current CURE shareholders. the transaction is subject to the completion of satisfactory due diligence, the parties entering into a definitive agreement with respect to the Transaction on or before November 30, 2023, the completion of a private placement by Atriva or CURE and the approval of the shareholders of the Company and Atriva, and the approval of the CSE and other applicable regulatory authorities. The transaction was expected to close from March 31, 2024 to June 30, 2024.

Atriva Therapeutics GmbH cancelled the acquisition of Biocure Technology Inc. (CNSX:CURE) on June 30, 2024. There was no penalty or termination fee payable by either the Biocure Technology or Atriva in connection with the termination of the agreement.